
Amyl Therapeutics bags €11m Series A extension
Amyl Therapeutics SA has secured €5m Series A extension from long-term investors Merieux Equity Partners and Noshaq, together with Mr Evren Ucok as a...

Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie has become the latest big pharma company to target the hot antibody-drug conjugate market, acquiring ImmunoGen and its Elahere ADC for...

Unveiling prostate cancer's Achilles' heel
An international research team, including experts from IRB Barcelona, Max Planck Institute for Molecular Genetics, and BC Cancer, discovered a...